Table 5 |
|||||||
|
Outcome effect estimates |
|||||||
|
Outcome |
N |
OR (95%CrI) |
P (%) |
τ (95%CrI) |
β (95%CrI) |
Pβ(%) |
|
|
|
|||||||
|
Mortality |
|||||||
|
High dose |
5 |
0.912 (0.313 to 1.253) |
42.0 |
1.00 (0.42 to 1.89) |
|||
|
High dose excluding Schumer [31] |
4 |
1.406 (0.727 to 2.614) |
89.3 |
0.25 (0.01 to 1.40) |
|||
|
Low dose |
9 |
0.796 (0.396 to 1.386) |
20.4 |
0.65 (0.23 to 1.44) |
|||
|
Low dose excluding CSG [32] |
8 |
0.706 (0.371 to 1.096) |
5.8 |
0.39 (0.04 to 1.15) |
|||
|
Corticotrophin responders* |
4 |
0.882 (0.285 to 2.073) |
36.4 |
0.49 (0.02 to 1.78) |
|||
|
Corticotrophin non-responders* |
4 |
0.831 (0.334 to 1.971) |
28.0 |
0.43 (0.02 to 1.69) |
|||
|
Shock-reversal |
|||||||
|
High dose |
2 |
1.078 (0.227 to 6.311) |
54.9 |
1.39 (0.06 to 1.93) |
|||
|
Low dose |
7 |
1.999 (1.069 to 4.55) |
98.2 |
0.57 (0.04 to 1.62) |
|||
|
Corticotrophin responders* |
3 |
1.830 (0.499 to 7.845) |
86.7 |
0.87 (0.05 to -1.92) |
|||
|
Corticotrophin non-responders* |
3 |
1.845 (0.637 to 7.267) |
91.9 |
0.55 (0.02 to 1.86) |
|||
|
Meta-regression (log odds mortality) |
|||||||
|
Average age |
High dose |
4 |
0.777 (0.285 to 2.426) |
27.3 |
0.72 (0.04 to 1.87) |
0.60 (-0.23 to 1.51) |
94.52 |
|
Excl Schumer [31] |
3 |
1.390 (0.399 to 4.872) |
77.0 |
0.66 (0.03 to 1.90) |
0.10 (-1.57 to 1.74) |
58.05 |
|
|
Low dose |
6 |
0.658 (0.334 to 1.223) |
7.6 |
0.36 (0.02 to 1.51) |
0.05 (-0.10 to 0.18) |
80.53 |
|
|
Underlying risk |
High dose |
5 |
0.943 (0.292 to 3.049) |
45.4 |
1.14 (0.46 to 1.49) |
0.23 (-1.71 to 2.58) |
60.98 |
|
Excl Schumer [31] |
4 |
1.372 (0.596 to 3.249) |
82.9 |
0.38 (0.01 to 1.74) |
-0.09 (-1.31 to 1.42) |
41.47 |
|
|
Low dose |
9 |
0.752 (0.389 to 1.291) |
14.5 |
0.57 (0.17 to 1.37) |
-0.49 (-1.14 to 0.27) |
7.80 |
|
|
Excl CSG [32] |
8 |
0.676 (0.347 to 1.076) |
4.9 |
0.40 (0.03 to 1.23) |
-0.28 (-0.88 to 0.50) |
19.08 |
|
|
Odds of the following complications (corticosteroids versus control) |
|||||||
|
Superinfection |
High dose |
4 |
1.127 (0.364 to 3.924) |
62.2 |
0.55 (0.02 to 2.85) |
||
|
Low dose |
6 |
0.955 (0.388 to 1.749) |
43.6 |
0.46 (0.03 to 1.62) |
|||
|
GI bleeding |
High dose |
3 |
0.824 (0.167 to 3.186) |
37.3 |
0.74 (0.03 to 1.90) |
||
|
Low dose |
5 |
1.103 (0.379 to 3.031) |
59.6 |
0.58 (0.02 to 1.84) |
|||
|
Hyperglycemia |
High dose |
3 |
1.012 (0.244 to 4.266) |
50.8 |
0.64 (0.03 to 1.88) |
||
|
Low dose |
3 |
1.430 (0.155 to 3.985) |
57.4 |
0.87 (0.05 to 1.93) |
|||
|
|
|||||||
|
*all studies were low dose; CI, confidence interval; CSG, Cooperative Study Group; GI, gastro-intestinal; N, number of studies reporting data for that endpoint; NA, not applicable; OR, odds ratio. Excl Sch = Excluding Schumer [31]; Excl CSG = Excluding CSG [32] |
|||||||
|
Moran et al. Critical Care 2010 14:R134 doi:10.1186/cc9182 |
|||||||
